Journal of Clinical Trials
Open Access

Abstract

Examining Clinical Trial Interest and Motivators among Diverse Populations Across a Comprehensive Cancer Center's Catchment Area

Nathanael B. Stanley*, Vani N. Simmons, Biwei Cao, Jennifer I. Vidrine, Shannon M. Christy, Brian D. Gonzalez, Kea Turner, Jessica Y. Islam, Brandon Blue, Kenisha Avery and Susan T. Vadaparampil

Introduction: Although diverse representation in cancer clinical trials is crucial for developing effective treatments for all populations, some groups remain underrepresented leading to disparities in treatment outcomes. What motivates someone to engage in a clinical trial can differ by racial and cultural background. This study explored possible motivators of clinical trial participation among diverse residents in a catchment area of an NCI-designated Comprehensive Cancer Center in the Southeastern United States.

Methods: Data were collected via a cross-sectional survey from January to March 2022, targeting residents within a 23-county area spanning Southeastern Florida (n=1,745). The survey assessed respondents’ interest in cancer clinical trial participation based on potential motivators, including health improvement, altruism, financial incentives and support services such as transportation. Ordinal logistic regression examined differences in clinical trial interest by race/ethnicity.

Results: Based on self-report, 16.8% (n=288) were previously invited to participate in a clinical trial. Among those invited, 45.1% (n=130) reported having participated in a clinical trial. Compared to NH Whites, Hispanic (OR=0.58, p=0.0004) and NH Black respondents (OR=0.65, p=0.0001) were less likely to be influenced by the ability to get better. Additionally, Hispanic (OR=0.81, p=0.0432) and Non Hispanic Other respondents (OR=0.59, p=0.0389) were less likely to be influenced by having treatment costs covered that were not covered by insurance.

Conclusion: Understanding racial and ethnic differences in factors influencing cancer clinical trial participation can guide strategies to improve diversity in clinical trials. Addressing these motivators through culturally tailored approaches may enhance participation and contribute to more equitable healthcare outcomes.

Published Date: 2025-07-10; Received Date: 2025-06-05